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Cells infected with vaccinia viruses expressing the equine 
infectious anaemia virus (EIAV) gag gene (VGag) or gag 
plus the 5' pol  encoding protease (VGag/PR) were 
evaluated with monoclonal antibody to a p26 capsid 
protein linear epitope (QEISKFLTD). Both recombin- 
ant viruses expressed Gag precursor protein (55K) 
whereas only VGag/PR expressed a detectable Gag-Pol 
fusion protein (82K) with a functional protease, shown 
by subviral particles containing processed p26. Horses 
inoculated with VGag/PR produced antibodies reactive 
with EIAV Gag proteins. 
Horses infected with equine infectious anaemia virus 
(EIAV) have a life-long infection, characterized in the 
first few months by recurrent viraemia with fever, 
anaemia, and thrombocytopenia (Cheevers & McGuire, 
1988; Clabough et al., 1991). During viremic episodes, 
cell-free antigenic variants defined by in vitro neutralizing 
antibody assays can be isolated from plasma (Kono et 
al., 1973). Mutations occurring in the env gene encoding 
gp90 and gp45 cause these antigenic variants (Montelaro 
et al., 1984; Payne et al., 1987). Despite variation of 
neutralization-sensitive epitopes and other mechanisms 
of viral escape, most EIAV-infected horses eventually 
become clinically quiescent carriers (Kono et at., 1976). 
That lymphocyte responses are involved in EIAV control 
is demonstrated by the failure of foals with congenital 
severe combined immunodeficiency, which lack B and T 
lymphocytes, to terminate viraemia (Perryman et at., 
1988). Also, EIAV carrier horses treated with immuno- 
suppressive drugs have viraemic episodes (Kono et al., 
1976). 
EIAV could be controlled by several potentially 
protective immune responses including neutralizing 
antibody, cytotoxic T lymphocytes or antibody-depen- 
dent mechanisms of cytotoxicity. Studies of protective 
immune responses to lentiviruses have emphasized 
envelope glycoproteins. However, some have demon- 
strated cytotoxic T lymphocyte responses to human 
immunodeficiency virus type 1 (HIV-1) and simian 
immunodeficiency virus Gag proteins (Riviere et al., 
1989; Johnson et aL, 1991 ; Littaua et aL, 1991 ; Yasuhiro 
et al., 1993). Immune responses to epitopes on the gag- 
encoded proteins may be important because the rate of 
divergence in gag is low compared to env in HIV-1 (Li et 
al., 1988) and in EIAV (Perry et al., 1992). The EIAV gag 
gene contains 1458 nucleotides (nt) encoding a 55K Gag 
precursor protein (Montelaro et al., 1982; Stephens et 
at., 1986; Hussain et at., 1988) which is proteolytically 
cleaved into proteins including p15 matrix, p26 capsid, 
p 11 nucleocapsid, and p9 of unknown function (Hender- 
son et al., 1987). A 10K protease encoded by the EIAV 
pol  gene and expressed in Escherichia coli cleaves the Gag 
precursor to yield p26 (Rushlow et aL, 1992). To evaluate 
Gag protein synthesis and processing in eukaryotic cells 
and to aid the dissection of immune responses to Gag 
proteins, recombinant vaccinia viruses expressing EIAV 
Gag proteins and protease were evaluated. 
Viral RNA for cDNA cloning was isolated (O'Rourke 
et al., 1991) from EIAV-WSU5, a pathogenic cell culture- 
adapted strain isolated after three sequential passages of 
prototype EIAV in horses and then three limiting 
dilutions in cell cultures (O'Rourke et al., 1988). First- 
strand synthesis was primed with an oligonucleotide 
corresponding to nt 2582 to 2599 of prototype EIAV 
provirus (Kawakami et al., 1987) followed by second- 
strand synthesis (Gubler & Hoffman, 1983). Plasmids 
made by annealing dG-tailed cDNA to dC-tailed pUC19 
were used to transform DH5~ E. coli. Isolated plasmid 
pEIA5G contained a 2.2 kb EIAV cDNA insert and 
both strands were sequenced (GenBank accession no. 
L06609) using the dideoxynucleotide chain termination 
method. The sequence corresponded to nt 340 to 2578 of 
prototype provirus (Fig. 1) with the 1458 nt EIAV- 
WSU5 gag sequence being identical to that of prototype 
gag (Kawakami et al., 1987). However, there were three 
0001-1972 © 1994 SGM 
896 Short communication 
gag 
gag~olpl5] p26 } pll }p9] po[ 
regaon 465 
pEIA5GI340 
VGag/PR ] 394 
VGag 1394 
! VR ! RT 3376 % 
2578] 
25261 
I937[ 
Fig. 1. Diagram of EIAV genes used to construct recombinant vaccinia 
viruses. EIAV proviral gag and 5' pol (from Kawakami et al,, 1987; the 
complete pol extends to nt 5120) is at the top followed by a cDNA clone 
of the EIAV-WSU5 gag and 5' pol in pEIA5G and the fragments of 
pEIA5G used to construct recombinant vaccima viruses, VGag/PR 
and VGag. RT, Reverse transcriptase. 
g 
nucleotide differences in 5' poh an A at position 2058 
changing arginine to lysine in the predicted protease 
sequence, a synonymous C at 2341, and an A at 2441 
changing glycine to serine in the predicted reverse 
transcriptase. By comparison, the WSU5 env gene has 
13 nt and six amino acid differences from the 2580 nt of  
prototype env (McGuire et al., 1990). Like prototype 
EIAV, expression of  Pol proteins from the WSU5 
gag-pol transcript requires a ribosomal frameshift 
(Stephens et al., 1986). The frameshift may occur at a 
heptanucleotide site associated with ribosomal frame- 
shifting in other retroviruses (Hatfield et al., 1992) and 
predicted for EIAV (Montelaro et al., 1993); this is 
A A A A A A C  located 40 nt into the gag-pol gene overlap. 
To identify EIAV Gag proteins expressed by recombin- 
ant viruses, a monoclonal antibody (MAb) binding p26 
was defined. The hybridoma producing MAb EIA6A1, 
an IgG1 isotype, was derived by fusing spleen cells from 
a BALB/c  mouse immunized with EIAV prototype 
strain with X63.AG8.653 myeloma cells and cloned 
twice by limiting dilution (Davis et al., 1983). This MAb 
reacted in immunoblots with 55K and 26K EIAV 
proteins and two other minor proteins (Fig. 2 a, lane 7). 
The specificity of MAb EIA6A1 for p26 was defined by 
mapping the epitope using overlapping hexamers of  the 
p26 amino acid sequence synthesized on plastic pegs 
(Geysen et al., 1984; Cambridge Research Biochemicals). 
Significant MAb EIA6A1 binding occurred with hex- 
amers encompassing the amino acid sequence QEISKF- 
LTD (Table 1) corresponding to amino acids 179 to 187 
of  processed p26 (Stephens et al., 1986). This epitope is 
also in the 83 amino acid C terminus of p26 previously 
identified as a highly immunogenic domain (Chong et al., 
1991). 
To demonstrate that the EIAV 55K Gag precursor 
was processed by the pol-encoded protease rather than 
cellular proteases and to have vectors which correctly 
processed Gag proteins, two recombinant vaccinia 
viruses were made. VGag contained only the gag gene 
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Fig. 2. Immunoblot of recombinant vaccmia virus-expressed gag 
proteins. (a) Lysates from HeLa cells (lanes 1 to 3) and equine kidney 
cells (lanes 4 to 6) infected with VGag/PR. VGag or VSCll, 
respectively, and 2 gg EIAV (lane 7) were reacted with MAb EIA6A1. 
(b) Lysates of TK- 143B cells (lanes 1 to 3) infected with VGag/PR, 
VGag or VSC11, were reacted with serum from horse A-1924 taken 60 
days after EIAV infection. Neither an isotype control MAb nor 
preinfectlon serum from A-1924 reacted with duplicate immunoblots 
(data not shown). M~. standards are shown on the left. 
Table 1. Reactivity of  MAb  EIA6A1 with overlapping 
hexamers derived from the EIA V p26 amino acid 
sequence 
Amino acid 
Peptide no. sequence ELISA A40 s 
180 GHPQEI 0"017 
181 HPQEIS 0"016 
182 PQEISK 0"012 
183 QEISKF 0"202* 
184 EISKFL 0"306* 
185 ISKFLT 0"298* 
186 SKFLTD 0" 122* 
187 KFLTDT 0"027 
188 FLTDTL 0"016 
189 LTDTLT 0"015 
* The A~0 s values for peptides 1 to 182 and 187 to 250 did not exceed 
0.032. 
(Fig. 1) and was made with an insertion plasmid derived 
by ligating the SmaI-XbaI  fragment of EIAV c D N A  
from pEIA5G containing nt 394 to 1937 (Kawakami et 
aL, 1987) to Sinai-digested pSCl l  (Chakrabarti et al., 
1985). Prior to ligation, the 5' overhang resulting from 
the XbaI digest was filled using the Klenow fragment of 
D N A  polymerase I. The Sinai cloning site in pSC11 is 
downstream of the P7"5 vaccinia virus promoter and the 
translation initiation codon for the cloned EIAV gag 
gene was the first ATG in the SmaI-XbI  fragment which 
was located 72 nt downstream from the Sinai site. 
V G a g / P R  contained gag and 5' pol genes encoding 
protease (Fig. 1). V G a g / P R  was made with an insertion 
plasmid derived by ligating the Sinai fragment from 
pEIA5G containing nt 394 to 2526 to SmaI-digested 
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pSC11. It was predicted to make the Gag precursor and 
also to have a ribosomal frameshift to produce a 
detectable Gag-Pol fusion protein (Stephens et al., 
1986). A control vaccinia virus, VSCll, was made with 
pSCll without an EIAV cDNA insert. The insertion 
plasmids were characterized by restriction endonuclease 
digestion and nucleotide sequencing of all ligation sites. 
The insertion plasmid, pSCll,  also contains the fl- 
galactosidase gene driven by the P l l  vaccinia virus 
promoter (Chakrabarti et al., 1985) and following 
homologous recombination with vaccinia virus WR 
strain in infected cells, 5-bromo-4-chloro-3-indolyl-D- 
galactopyranoside was added to the agarose overlay 
allowing visual detection of recombinant virus as a blue 
plaque. Selected recombinants were plaque-purified three 
times in BSC-1 cells. 
The Gag proteins made by recombinant vaccinia 
viruses were identified by immunoblotting infected cell 
lysates. HeLa and neonatal equine kidney cells, in wells 
of a 24-well plate, were infected with 10p.f.u./cell 
for 24 h. Infected cells were lysed with 0"5 % NP40 in 
50 mM-Tris-HC1 pH 8, containing 5 mM-EDTA, 5 mM- 
iodoacetamide, 0.1 mM-TLCK and 1 mM-PMSF for 
30rain on ice and centrifuged at 12000g for 5min. 
Proteins in the supernatant were separated by SDS- 
PAGE, transferred to nitrocellulose and probed with 
either MAb or serum from an Arabian horse 60 days 
after infection with EIAV-WSU5 (Perryman et al., 1988). 
Bound primary antibodies were detected with either anti- 
mouse or anti-horse immunoglobulin antibodies conju- 
gated to horseradish peroxidase and substrate for 
chemiluminescence (McGuire et al., 1992). Cell cultures 
infected with VGag and VGag/PR produced a 55K 
protein, identified as the Gag precursor by its size and 
reactivity in immunoblots with MAb EIA6AI (Fig. 2a, 
lanes 1, 2, 4 and 5). In addition, cell cultures infected with 
VGag/PR, but not VGag, expressed an 82K protein 
reactive with MAb EIA6A1 (Fig. 2a, lanes 1 and 4). This 
protein corresponded to the predicted truncated Gag-Pol 
fusion protein beginning with an initiation codon at nt 
465, having a ribosomal frameshift in the overlap region, 
and continuing through nt 2526 to a termination codon 
18 nt downstream in pSC11. IfVGag encoded a Gag-Pol 
fusion protein involving the 244 nt overlap region, it was 
predicted to be approximately 55K and indistinguishable 
from the 55K Gag precursor protein by immunoblots 
using the antibodies described. Reactivity of MAb 
EIA6A1 with isolated EIAV resulted in a strong p26 
band and a weak reaction with the 55K precursor protein 
(Fig. 2a, lane 7), presumably because of the low amount 
of this latter protein in EIAV. Serum antibodies from an 
EIA¥-infected horse bound both the 55K and 82K 
proteins in cell lysates whereas serum taken before 
infection did not bind these proteins (Fig. 2b). p26 was 
not demonstrated in any of these immunoblots; however, 
MAb EIA6A1 bound 41K, 44K, 47K and 50K proteins 
in lysates from VGag- and VGag/PR-infected HeLa cells 
(Fig. 2a, lanes 1 and 2) and horse serum antibodies to 
EIAV bound similar proteins in VGag- and VGag/PR- 
infected thymidine kinase-negative (TK)  143B cells 
(Fig. 2 b). Since these partially processed Gag proteins 
were present in lysates of cells infected with either 
construct, they did not result from the protease encoded 
by EIAV pol. It is likely these fragments were generated 
by cellular or vaccinia virus proteases. Cells infected with 
a recombinant vaccinia virus expressing HIV-1 gag-pol  
genes processed the 55K Gag precursor to p24 with three 
intermediates including p39, p41a and p41b (Gowda et 
al., 1989a). Whether these HIV-1 Gag protein inter- 
mediates are similar to EIAV Gag proteins described 
above and attributed to cellular or vaccinia virus 
proteases is unknown. 
Failure to detect p26 in recombinant virus-infected cell 
lysates prompted an examination of these cells for 
subviral particles which might contain processed p26 
(Gowda et aI., 1989b; Karacostas et al., 1989). For 
transmission electron microscopy, equine kidney cells in 
25 cm 2 tissue culture flasks were inoculated with 10 
Fig. 3. Electron mmrographs of retrovirus-like particles in thin sections 
of VGag/PR-infected equine kidney cells. Both vaccinia virus particles 
(V) and incomplete EIAV particles (arrowheads) are present in the 
cytoplasm. Bar represents 200nm. Inset: retrovirus-like particles 
budding from the cell membrane; bar represents 100 nm. 
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Fig. 4. I m m u n o b l o t  of  subvl ra l  par t ic les  i so la ted  f rom r ecombinan t  
vacc in ia  virus- infected cell cultures.  Lanes  1 to 3 con t a ined  par t ic les  
i so la ted  f rom cul ture  supe rna tan t s  f rom equine  k idney  cells infected 
wi th  VSC11, V G a g / P R  and  VGag ,  respectively.  Al l  lanes  were reacted 
wi th  M A b  EIA6A1.  A n  isotype cont ro l  M A b  did no t  react  w i th  a 
dup l ica te  i m m u n o b l o t  M r s t anda rds  are shown  on the left. 
p.f.u./cell of either VGag/PR, VGag or VSC11. After 
24 h, cells were fixed with 4 % paraformaldehyde/2 % 
glutaraldehyde in 0.1 M-cacodylate buffer at pH 7.4. 
Fixed cells were removed by scraping, pelleted in agarose, 
post-fixed in 1% osmium tetroxide, and embedded in 
Epon. Ten ultrathin sections from each group were 
stained with uranyl acetate and lead citrate and ex- 
amined. Cells infected with VGag/PR had both 
retrovirus-like particles and vaccinia virus particles that 
were distinguishable by size and morphology (Fig. 3). 
The retrovirus-like particles in VGag/PR-infected cells 
were not complete and were found free in the cytoplasm 
and budding from the cell membrane. Budding particles 
had a double-layered membrane with an electron-lucent 
centre and ranged from 90 to 110 nm in diameter (Fig. 
3). Their morphology was similar to the particles 
described in cells infected with recombinant vaccinia 
virus or baculoviruses expressing the HIV-1 gag gene 
(Karacostas et al., 1989; Gheysen et al., 1989). Cells 
infected with VGag had subviral and vaccinia virus 
particles similar to those described for VGag/PR 
whereas cells infected with VSC 11 had vaccinia virus, but 
no subviral retrovirus-like particles. 
To examine subviral particles for p26, they were 
isolated and immunoblotted as described for cell lysates. 
Particles were removed from culture medium by centri- 
fugation at 120000 g for 3 h, resuspended in PBS, layered 
200K - 
97-4K --  
69K - -  
1 2 3 4 5 6 
46K - alt-,~, 
30K - 
20 1K --  
14-3K - 
m o o  
Fig. 5. I m m u n o b l o t  o f  E I A V  pro te ins  wi th  an t ibod ies  f rom horses  
i m m u n i z e d  wi th  V G a g / P R .  Every  lane  con ta ined  0.5 Ixg E I A V  and  all  
an t ibodies  were d i lu ted  500-fold. Lanes  1 and  2 were reacted wi th  sera 
f rom V G a g / P R - i m m u n i z e d  horses  H-472 and  H481, respectively.  
Lanes  3 and  6 were reacted wi th  sera f rom horse  A-1924 af ter  and  
before  E1AV infection,  respectively.  Lanes  4 and  5 were reacted wi th  
sera f rom VSC11- immunized  horses  H-479 and  H-482,  respectively.  M r 
s t anda rds  are shown  on  the left. 
onto a 15 % sucrose cushion, and centrifuged at 120 000 g 
for 90 rain (Haffar et al., 1991). Particles from VGag/PR- 
infected cells, and not from VGag-infected cells, con- 
tained processed p26 which reacted with MAb EIA6A1 
(Fig. 4) demonstrating that processing of the p26 
depended on the viral protease. Presence of capsid 
protein in EIAV subviral particles here and in HIV-1 
particles (Gowda et al., 1989b; Karacostas et al., 1989) 
may be accounted for by protease cleavage of Gag 
precursor protein after particle assembly. 
To determine whether VGag/PR would induce an 
immune response to EIAV Gag proteins, two horses 
(Shetland ponies H-472 and H-481) were immunized 
intradermally in each of four locations with l0 s p.f.u, of 
VGag/PR and were boosted with the same dose at 4 and 
12 months later. Two control horses (Shetland ponies H- 
479 and H-482) were similarly immunized with VSC11. 
Sera collected 2 weeks after the last boost were analysed 
for antibodies to EIAV by immunoblotting. The VGag/ 
PR-immunized horses produced antibodies to EIAV 
Gag proteins, particularly p26 (Fig. 5, lanes 1 and 2). 
Longer development of these immunoblots demon- 
strated antibodies to p15 and p l l  proteins (data not 
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shown). The VSC11-immunized horses did not produce 
antibodies to EIAV Gag proteins (Fig. 5, lanes 4 and 5). 
Several conclusions can be drawn from the structural 
analysis of the EIAV gag and 5' pol genes and the 
functional and immunological analysis of Gag proteins 
produced by recombinant vaccinia viruses. (i) Following 
sequential in vivo passages, the gag precursor sequence 
was more highly conserved in the clone we sequenced 
than either the 5' pol or env sequence. (ii) Cells infected 
with VGag/PR expressing the gag and 5' po! genes 
produced a predicted 82K Gag-Pol fusion protein 
demonstrating that the ribosomal frameshift necessary 
for translation of the protease gene from the gag-pol 
transcript occurred. (iii) The protease in the 82K 
Gag-Pol fusion protein was functional in equine cells 
(the only cell line examined for subviral particles) since 
the 55K Gag precursor was processed to p26 in subviral 
particles. This also indicated that the viral protease was 
unaffected by a naturally occurring mutation changing 
arginine to lysine. (iv) Expressed Gag proteins were 
bound by antibodies in serum from an EIAV-infected 
horse, and horses immunized with VGag/PR produced 
antibodies which bound EIAV Gag proteins. Based on 
these results, recombinant vaccinia virus VGag/PR 
produced functional Gag proteins and can be used 
further to examine T lymphocyte responses in EIAV 
carriers. 
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